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The efficacy of Mycobacterium bovis bacillus Calmette-Guérin (BCG) vaccine against pulmonary tuberculosis
(TB) varies enormously in different populations. The prevailing hypothesis attributes this variation to inter-
actions between the vaccine and mycobacteria common in the environment, but the precise mechanism has so
far not been clarified. Our study demonstrates that prior exposure to live environmental mycobacteria can
result in a broad immune response that is recalled rapidly after BCG vaccination and controls the multipli-
cation of the vaccine. In these sensitized mice, BCG elicits only a transient immune response with a low
frequency of mycobacterium-specific cells and no protective immunity against TB. In contrast, the efficacy of
TB subunit vaccines was unaffected by prior exposure to environmental mycobacteria. Six different isolates
from soil and sputum samples from Karonga district in Northern Malawi (a region in which BCG vaccination
has no effect against pulmonary TB) were investigated in the mouse model, and two strains of the Mycobac-
terium avium complex were found to block BCG activity completely.
Tuberculosis (TB) is one of the most prevalent causes of
death from infectious diseases in the world. As is the case for
many intracellular pathogens, cell-mediated immunity plays an
important role in host protection against TB (25, 29). In par-
ticular, gamma interferon (IFN-)-secreting T cells have been
shown to be important for the protective immune response
(17). The only vaccine currently available against TB is the
attenuated Mycobacterium bovis strain bacillus Calmette-
Guérin (BCG). The efficacy of this vaccine varies from 0 to
80% in different populations, with a consistently low efficacy in
many tropical regions of the world where the vaccine is most
needed (15, 16, 35, 38). The reason for the failure of BCG in
some populations has been a subject of debate since the 1950s,
and many different hypotheses have been suggested to explain
the observed variation. Some investigators have suggested that
differences in the strain of BCG (23), the age at vaccination
(40), or methodological differences are important factors for
the variation reported (8). The most widely accepted hypoth-
esis relates the efficacy of BCG to geographic location, with
low to nondetectable levels of protection against pulmonary
TB seen in tropical regions such as Africa and India, where
exposure to nontuberculous mycobacteria is common (15).
One exception from this general rule is the consistent high
efficacy when BCG is used to vaccinate newborns. Neonatal
vaccination with BCG imparts protection against the child-
hood manifestations of TB (in particular, meningitis) (1, 9, 24),
but the efficacy wanes over a period of 10 to 15 years, and
therefore it does not prevent against the later breakdown with
pulmonary TB in the adult population in the third world (37).
There is convincing evidence that exposure of laboratory
animals to environmental mycobacteria can provide some pro-
tection against infection with M. tuberculosis (7, 14, 20, 30, 33).
The influence of such cross protection on the efficacy of sub-
sequent BCG vaccination is not yet clarified, but based on
animal experiments, it has been suggested that the protection
provided by environmental mycobacteria may partly mask the
effect of a subsequent BCG vaccination (33, 42) or that envi-
ronmental mycobacteria have a direct antagonistic influence
on subsequent BCG vaccination (34, 36). Our study demon-
strates that prior sensitization with environmental mycobacte-
ria can inhibit BCG multiplication and thereby prevent the
induction of an efficient BCG-mediated immune response and
protection against TB challenge. Interestingly, different species
isolated from soil and sputum in Karonga, Malawi, an area in
which BCG has been shown to provide no protection against
TB (22), differed in their ability to inhibit BCG multiplication.
In contrast, a TB subunit vaccine had the same protective
effect in naive and sensitized animals.
MATERIALS AND METHODS
Animals. These studies were performed with pathogen-free 6- to 12-week-old
CBA/J and C57BL/6J female mice, purchased from Bomholtegaard, Ry, Den-
mark, or, in some of the experiments, purchased from Harlan UK, Ltd., Belton,
England, or Harlan Interfauna Ibérica, Barcelona, Spain.
Bacteria. Mycobacterium avium (ATCC 15769), Mycobacterium scrofulaceum
(ATCC 19275), and Mycobacterium vaccae (ATCC 15483) were grown in 7H9 broth
until the mid-log phase of the bacterial growth. Mycobacterium tuberculosis (Edman)
was grown at 37°C on Löwenstein-Jensen medium or in suspension in modified
Sauton medium enriched with 0.5% sodium pyruvate and 0.5% glucose. In prepa-
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ration for immunization of mice, frozen aliquots of the bacterial strains were thawed
and sonicated for 5 min with a Branson 2210 ultrasonifier, and the viability of each
strain was enumerated on 7H11 plates. Mycobacterium fortuitum (S78/2) and M.
fortuitum (S160/5) are soil isolates from the north and south of Karonga, Malawi,
respectively. We used standard decontamination of samples with 4% sodium hy-
droxide and culture at 37°C on nutrient agar-based medium to isolate the organisms
from soil. M. fortuitum (Sp2001), Mycobacterium chelonae (Sp2015), and two strains
of the M. avium complex (Sp1891) and (Sp2011) were sputum isolates from donors
with suspected TB in the Karonga district. The organisms were isolated with acidi-
fied Löwenstein-Jensen medium in Malawi, and their identity was confirmed at the
Mycobacterium Reference Unit, Dulwich, United Kingdom, by standard biochem-
ical identification tests for mycobacteria. Frozen aliquots of these strains were pre-
pared for animal inoculation as described above.
Sensitization with environmental mycobacteria. Mice were immunized subcu-
taneously (s.c.) in the back three times at 2-week intervals with 2 106 CFU of each
of three ATCC strains of environmental mycobacteria (M. avium, M. scrofulaceum,
and M. vaccae). To clear the remaining mycobacteria, sensitization was followed, 3
weeks after the last inoculation, by 1 month of treatment with rifampin (Sigma; 100
mg/liter), ethambutol (Sigma; 200 mg/liter), and clarithromycin (Abbott Laborato-
ries, Solna, Sweden; 200 mg/liter) added to the drinking water.
To assess virulence of the strains isolated from Karonga, Malawi, mice were
infected with 105 CFU of each environmental mycobacterial strain in a volume
of 0.2 ml of phosphate-buffered saline by intravenous (i.v.) injection via a lateral
tail vein. At the appropriate time points, mice were killed (four in each group),
and the organs were removed for bacterial enumeration. Whole organs were
homogenized in a 0.04% Tween 80 (Sigma) solution in distilled water, serial
10-fold dilutions were plated on Middlebrook 7H10 medium at 37°C, and the
numbers of CFU were determined.
Vaccinations. A single dose of BCG Danish 1331 (5  104 CFU) was injected
s.c. at the base of the tail. There were no significant differences in the protection
obtained with doses ranging from 5  104 to 107 BCG bacteria (results not
shown). In one experiment, an i.v dose of 5  106 CFU of BCG was used to
determine growth of BCG in naive versus sensitized mice. For subunit vaccina-
tion, the mice were immunized s.c. three times at 2-week intervals with 10 g
(per dose) of either ESAT-6 or the Ag85B–ESAT-6 fusion protein emulsified in
dioctadecylammonium bromide (DDA; 250 g/dose; Eastman Kodak, Inc.,
Rochester, N.Y.) plus 25 g of monophosphoryl lipid A (MPL; Corixa, Hamil-
ton, Mont.) as described recently (5).
M. tuberculosis infections. Animals were infected with approximately 100 CFU
of M. tuberculosis (Edman) per lung by the aerosol route in a Glas-Col inhalation
exposure system. The mice were sacrificed 6 weeks after infection, and bacterial
numbers in the lung and spleen were determined as described before (5).
The protective effect of BCG or subunit vaccination was expressed as the log10
reduction of the bacterial counts compared to that in the unvaccinated control
mice. All results are based on five or six animals per group.
Mycobacterial antigens. A crude BCG antigen preparation (BCG Ag) was
produced as an ammonium sulfate-precipitated culture filtrate from cultures at
week 6 as described in reference 2. In one of the experiments (see Fig. 4), the
BCG responses to an ammonium sulfate-precipitated extract of the cell wall were
measured as described elsewhere (31). These two preparations were found to
give similar responses in vitro.
Protein concentration was quantified by the Micro bicinchoninic acid method
(Pierce, Rockford, Ill.).
Recombinant ESAT-6 was produced as described previously (18). The LPS
content was below 0.3 ng/g of protein and had no influence on cellular activity.
The fusion protein Ag85B–ESAT-6 was produced as described recently (26). The
proteins were kept at 80°C until use.
Lymphocyte cultures. Lymphocytes from spleens and blood were isolated and
cultured as described previously (5). Briefly, cells from individual mice were
cultured in microtiter wells (96 well; Nunc, Roskilde, Denmark) containing 2 
105 cells in a volume of 200 l of RPMI 1640 supplemented with 5  105 M
2-mercaptoethanol, penicillin-streptomycin, 1 mM glutamine, and 5% (vol/vol)
fetal calf serum. Based on previous dose-response investigations, BCG Ag and
ESAT-6 were each used at 5 g/ml in the cultures. Phytohemagglutinin at a
concentration of 1 g/ml was used in all experiments as a positive control for cell
viability. IFN-, interleukin 4 (IL-4), and IL-5 were detected in 72-h culture
supernatants by duplicate enzyme-linked immunosorbent assay (ELISA).
Enzyme-linked immunospot (ELISPOT) analyses were conducted with cells
from individual mice or, when blood was analyzed, with cells pooled from groups
of mice, as described in reference 6. The detection level was 10 spots.
Statistical methods. Because all of the data show a normal distribution, the
assessment of experiments was carried out by analysis of variance. Differences
between means were assessed by Dunnett’s test (Tables 1 and 2) or Student’s t
test (see Fig. 2 and 4). A P value of 0.05 was considered significant.
RESULTS
The multiplication of BCG is inhibited in mice sensitized
with certain environmental mycobacteria. We inoculated
CBA/J mice s.c. three times at 2-week intervals with a mixture
TABLE 1. Sensitization with environmental mycobacteria
blocks the protective effect of BCG
Group of micea
Result inb:
Spleen Lung
CFUc Log10resistanced CFU
Log10
resistance
Naive 4.44  0.13 6.34  0.11
BCG 3.76  0.16 0.68* 5.21  0.08 1.13*
Sensitization 4.36  0.17 0.08 6.14  0.11 0.20
Sensitization  BCG 4.33  0.17 0.11 6.25  0.06 0.09
a Naive or sensitized mice were BCG vaccinated (5  104 CFU) followed by
aerosol challenge with virulent M. tuberculosis.
b The experiment was repeated twice with similar results.
c Bacterial numbers determined by growth of individual whole-organ homog-
enates 6 weeks postinfection.
d Protective effect expressed as the log10 reduction in bacterial loads compared
to those of naive mice. Bacterial numbers significantly different (P  0.05) from
those seen in naive mice are indicated by an asterisk.
TABLE 2. Bacterial numbers in organs of naive and sensitized
mice after vaccination and aerosol challenge
with virulent M. tuberculosis
Vaccine groupa
Result in:
Lung Spleen
Log10
CFUb
Log10
resistancec
Log10
CFU
Log10
resistance
Expt 1
Naive
Control 6.36  0.08 4.71  0.05
BCG 5.83 0.06 0.53* 4.12  0.12 0.59*
DDA-MPL 6.34 0.09 4.94  0.12
ESAT-6 5.76 0.09 0.60* 4.39  0.09 0.32*
Sensitized
Control 6.18  0.08 4.82  0.16
BCG 6.27 0.07 0.05 4.79 0.05 0.05
DDA-MPL 6.39 0.05 4.73  0.11
ESAT-6 5.74 0.16 0.44* 4.43  0.05 0.39
Expt 2
Naive
Control 6.88  0.12 5.10  0.18
DDA-MPL 7.19 0.05 5.48  0.11
Ag85B–ESAT-6 6.03 0.12 0.85* 4.40  0.08 0.70*
Sensitized
Control 6.30  0.08 4.39  0.09
DDA-MPL 6.49 0.05 4.27  0.08
Ag85B–ESAT-6 5.37 0.14 0.93* 3.89  0.07 0.50*
a Naive or sensitized mice were immunized s.c. with BCG or injected three
times with a subunit vaccine emulsified in DDA-MPL.
b Bacterial numbers are given as log10 CFU of M. tuberculosis isolated from the
lung and spleen 6 weeks after aerosol challenge with virulent M. tuberculosis.
c Protective effects of the two vaccines are expressed as log10 reductions in
bacterial numbers compared to those in unvaccinated control mice. Bacterial
numbers significantly different from those seen in control mice are indicated by
an asterisk.
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of the mycobacterial strains M. avium, M. scrofulaceum, and M.
vaccae. These species have repeatedly been isolated from soil
and water samples in tropical regions (21). Three weeks posti-
noculation, a low but significant mycobacterium-specific recall
response was measured in the spleen, with detectable levels of
IFN- release in response to BCG Ag. (1.26  0.01 ng/ml)
(data not shown). The BCG Ag preparation gave no IFN-
release (0.05 ng/ml) from splenocytes isolated from naive
mice. No IL-4 or IL-5 was detected in any of the supernatants.
Three weeks after the last inoculation with environmental my-
cobacteria, we subjected the mice to 4 weeks of chemotherapy
to clear remaining live mycobacteria. After the end of chemo-
therapy treatment, no environmental mycobacteria were de-
tected in any of the target organs (liver, spleen, and lymph
nodes).
We inoculated groups of sensitized and age-matched naive
CBA/J mice i.v. 1 week after the end of chemotherapy treat-
ment with 5  106 BCG and monitored the growth in the
spleen and liver over time. Sensitization with environmental
mycobacteria resulted in inhibition of the initial multiplication
of BCG in the spleen and liver (Fig. 1A). In naive mice, the
initial multiplication of BCG resulted in 10- to 30-fold more
bacteria in the spleen postinoculation than in sensitized mice.
A difference was also seen after a conventional s.c. vaccination,
although the bacterial numbers were at lower levels (data not
shown). Similar data were obtained with C57BL/6J mice, which
are more susceptible to BCG (11). In this strain, larger differ-
ences in BCG numbers were found between sensitized and
nonsensitized mice (Fig. 1B).
Immune responses induced by BCG vaccination in sensi-
tized and naive mice. We continued by investigating the im-
mune response induced by BCG in sensitized and age-matched
naive control CBA/J mice. ELISPOT was used to monitor
frequencies of BCG-specific T cells before and 3, 5, 8, and 11
weeks after the s.c. vaccination with BCG (Fig. 2). Before BCG
vaccination, no mycobacterium-specific IFN--producing T
cells were detected in any of the mice. Three weeks after BCG
inoculation, the number of BCG-specific IFN--producing
cells in the draining lymph nodes had increased and reached
the same level in sensitized and in naive mice (Fig. 2A). The
response in sensitized mice was, however, transient, and from
5 weeks after BCG inoculation and onwards, a higher fre-
quency of mycobacterium-specific cells was found in naive vac-
cinated mice. At the termination of the experiment (week 11),
a 10-times-higher frequency of BCG-specific T cells was
found in the naive vaccinated group than in the sensitized
vaccinated group (P  0.032). A similar dynamic development
of responses was found in the blood, although it was delayed so
FIG. 1. BCG multiplication is inhibited in mice previously sensi-
tized with environmental mycobacteria. (A) CBA/J mice. (B) C57BL/6J
mice. The growth of BCG was compared in naive mice (open symbols)
and in sensitized mice (solid symbols). The data shown are the means
of BCG CFU  standard errors. For both groups, five animals were
sacrificed for each time point. The experiment was repeated twice with
similar results.
FIG. 2. Influence of previous sensitization with environmental my-
cobacteria on the BCG-specific immune responses. BCG was admin-
istered s.c., and the frequencies of IFN--producing cells isolated from
the draining lymph nodes (A) and the blood (B) in naive mice (open
symbols) and sensitized mice (solid symbols) were detected by the
ELISPOT assay postvaccination after in vitro stimulation with BCG-
Ag. The data presented here represent the logarithmic mean of results
obtained from lymph node cells from three individual mice per group
 standard errors. The responses in the blood were analyzed on cells
pooled from three animals for each time-point. A pilot experiment
conducted on weeks 2, 4, and 6 supported the overall difference in the
response profiles of the two groups of animals.
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that higher frequencies of specific T cells were found from
week 8 onwards in naive vaccinated mice (Fig. 2B). At no time
point after vaccination was IL-4 or IL-5 detected in the super-
natants of the stimulated cultures (results not shown).
Sensitization with environmental mycobacteria blocks the
protective effect of BCG, but not a TB subunit vaccine. We
continued by vaccinating sensitized and naive age-matched
control CBA/J mice 4 to 5 weeks after the end of chemother-
apy-treatment, followed 2 months later by an aerosol challenge
with M. tuberculosis. The mice were killed 6 weeks post-TB
infection, and M. tuberculosis CFU were enumerated in the
lungs and spleens. The BCG vaccine imparted appreciable
protection to naive mice against the TB challenge, with signif-
icantly reduced bacterial numbers in the organs (0.68 to 1.13
log10 reduction; Table 1). Sensitization with environmental
mycobacteria on its own, or followed by BCG vaccination,
failed to induce a statistically significant level of protection
against TB (Table 1).
We also asked if a previous sensitization with environmental
mycobacteria would influence protection induced by a subunit
vaccine. Groups of naive and sensitized CBA/J mice were
vaccinated with BCG or injected (three times at 2-week inter-
vals) with recently developed TB subunit vaccines based on the
immunodominant antigens ESAT-6 and Ag85B mixed with a
DDA-MPL adjuvant emulsion (5, 26). ESAT-6-vaccinated an-
imals mounted a very strong recall immune response (5 to 7 ng
of IFN-/ml) to the homologous preparation 1 week postvac-
cination in the blood (data not shown). The protection ob-
tained by BCG in control mice was log 0.53, and as in the
previous experiment, BCG did not protect presensitized mice
(Table 2, experiment 1) The ESAT-6 subunit vaccine, in con-
trast, induced a similar degree of protection in both naive and
sensitized mice. A subunit vaccine based on a fusion protein of
Ag85B and ESAT-6 has recently been demonstrated to induce
levels of protection similar to those of BCG in the mouse
model (26), and this vaccine also protected against TB chal-
lenge at the same level in naive and sensitized mice (Table 2,
experiment 2).
Mycobacterial species isolated in Karonga, Malawi, differ in
their ability to block BCG activity. We investigated six differ-
ent isolates from soil and sputum samples from Karonga Dis-
trict in Northern Malawi in the mouse model. Three of these
isolates were typed as M. fortuitum, one was a strain of M.
chelonae, and two were classified as belonging to the M. avium
complex (Fig. 3). The growth of these isolates in spleen, liver,
and lung was investigated with C57BL/6J mice over a period of
30 days. Most of the isolates were rapidly cleared to below the
level of detection, but the strains from the M. avium complex
multiplied and reached bacterial numbers 3 logs above those of
M. chelonae and M. fortuitum after day 14 (Fig. 3). The mice
FIG. 3. Growth of isolates from Karonga, Malawi, in the mouse model. To evaluate the virulence of the isolates, mice were infected i.v. with
M. fortuitum strains S160 (open circles), S78/2 (solid circles), and 2001 (solid triangles); M. chelonae strain 2015 (open triangles); and M. avium
complex strains 1891 and 2011 (solid and open squares, respectively). The mycobacterial loads were determined in the liver, spleen, and lung at
the time points indicated. M. chelonae and M. fortuitum were all below the level of detection from day 14 onwards. Data are given as means with
standard errors (n  4).
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were treated with chemotherapy, followed by an injection of
BCG according to our standard protocol. BCG counts in the
spleen of these mice were quantified at week 2 postinoculation
(Fig. 4A). M. fortuitum and M. chelonae did not inhibit the
growth of BCG, whereas bacteria from the M. avium complex
reduced BCG numbers by 1 to 1.5 log (P  0.01). This differ-
ence correlated with the immune responses induced by the
BCG vaccine. There was no influence on the level of IFN-
responses to BCG Ag by sensitization with M. chelonae or M.
fortuitum, whereas the previous inoculation with bacteria from
the M. avium complex completely ablated BCG immune re-
sponses (Fig. 4B). All strains, on the other hand, induced low
and variable responses to antigens extracted from the homol-
ogous strain of environmental mycobacteria (results not
shown).
DISCUSSION
This study demonstrates that animals exposed to certain
environmental mycobacteria raise an immune response that
controls the multiplication of BCG, thereby curtailing the vac-
cine-induced immune response before it is fully developed.
The finding is important for the long-held discussion on the
failure of BCG vaccination against TB in some parts of the
world (15, 16, 38). One hypothesis to explain the failure of
BCG was presented in 1966 by Palmer and Long, based on
large-scale guinea pig experiments. They argued that because
contact with nontuberculous bacteria offers some level of pro-
tective immunity to TB, the protective effect of a superimposed
BCG vaccine would be masked (33). The present study con-
firms the classical observation that priming with environmental
mycobacteria promotes some levels of protective immunity to
other mycobacteria (7, 10, 14, 33), in this case to BCG. How-
ever, this effect was not sufficient to significantly reduce the
growth of M. tuberculosis, which multiplied at an almost un-
changed rate in these sensitized animals. The difference from
the partial protection imparted by environmental mycobacteria
in the guinea pig model (14, 33) may be related to the fact that
the earlier studies made no effort to clear the environmental
mycobacteria by chemotherapy before challenge with M. tuber-
culosis, as well as the different genetic makeup and suscepti-
bility of mice versus guinea pigs. The differences in these mod-
els and their relevance to human disease are the subject of an
ongoing study.
That prior sensitization to environmental mycobacteria in-
terferes in a similar way with human BCG vaccination is
FIG. 4. (A) Growth of BCG in sensitized and naive animals. Mice were infected s.c. with 2  106 CFU of either M. fortuitum, M. chelonae, or
M. avium or were left untreated. After chemotherapy, mice were infected with BCG Pasteur. BCG CFU in the spleen are shown as means with
standard errors (n  4). Statistically significant differences between sensitized (solid bars) and naive (open bars) mice are indicated: , P  0.05;
, P 0.01, according to Student’s t test. ND, not done. (B) Effects of sensitization on the IFN- response to BCG. Spleen cells were pooled from
four individual mice sensitized with the environmental strains (shaded bars), naive mice inoculated with BCG (open bars), or sensitized mice
inoculated with BCG (solid bars). IFN- production was assessed in the supernatants of spleen cell cultures stimulated in vitro with BCG Ag and
are given as means with standard errors. Statistically significant effects of sensitization on the response to BCG infection are labeled: , P  0.05;
, P  0.01, according to Student’s t test.
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strongly suggested by a number of classical epidemiological
observations: (i) the finding of strong efficacy of BCG in trials
in which tuberculin skin test-positive (and therefore sensitized)
donors have been vigorously excluded (19); (ii) the consistent
success with BCG in neonates vaccinated before any significant
sensitization from environmental mycobacteria occurs (1, 9,
24); and, (iii) finally, the observation of a lower rate of skin test
conversion, much smaller average diameter, and rapidly wan-
ing responses after BCG vaccination in areas with environmen-
tal sensitization (India and Egypt), compared with those in
areas with minimal environmental exposure (Denmark) (4,
32). This observation was recently confirmed and extended by
the observation of only minimal in vitro IFN- responses to
purified protein derivative (PPD) induced by BCG vaccination
in donors from Karonga, Malawi, compared to those from the
United Kingdom (P. E. Fine and H. Dockrell, personal com-
munication). Taken together, these findings are in agreement
with the low and transient immune response in the group of
animals sensitized with environmental mycobacteria before
vaccination, whereas the naive animals developed strong and
sustained responses (Fig. 3). Our experimental model is there-
fore relevant to the many tropical regions where BCG is not
protective against pulmonary TB and where the high incidence
of TB indicates that any partial protection provided by expo-
sure to environmental mycobacteria is insufficient for the pre-
vention of TB.
Our main conclusion is that BCG, as a live vaccine, is par-
ticularly sensitive to the influence of preexisting immune re-
sponses to antigens shared with certain environmental strains.
In this regard, a recent study has demonstrated the cross-
recognition of a large number of antigens shared between M.
avium and BCG (T. Pais and R. Appelberg, unpublished re-
sults). Multiplication is a precondition for the induction of
immunity by BCG and killing of BCG by chemotherapy after
administration has been demonstrated to abrogate subsequent
immunity completely (13, 39). In the present study, this block-
ing is achieved by immunological control instead of chemo-
therapy, but the outcome in both cases is interference with the
protective immune response, which would normally develop in
response to the growing BCG. The requirement for BCG mul-
tiplication can be explained as a simple consequence of dosage,
but more likely is due to the fact that only live BCG secretes
many antigens of importance for the induction of a protective
immune response (3, 28). Interestingly, our data from the
animal model also suggest that only environmental strains,
which are capable of an initial multiplication in the host, block
the activity of BCG. A detailed evaluation of a large number of
different soil isolates from Karonga, Malawi, and of their in-
teractions with BCG is ongoing. In the future, information on
the geographical distribution of such strains would be a valu-
able resource when trying to understand the huge variation in
BCG efficacy in human trials.
This inhibitory effect of the environmental mycobacteria on
the growth and activity of BCG provides an important argu-
ment in the ongoing discussion of live attenuated vaccines
versus nonviable subunit vaccines against TB (12, 27, 44). In
comparison with live attenuated vaccines, the present study
suggests that subunit vaccines may be much less influenced by
prior contact with environmental mycobacteria. As mentioned
above, neonatal BCG vaccination consistently imparts protec-
tion against the childhood manifestations of TB (mostly ex-
trapulmonary disease), but as its efficacy wanes over a period
of 10 to 15 years (37), the adult pulmonary manifestations of
TB are prevented neither by neonatal vaccination, by vaccina-
tion in adolescence after exposure to environmental mycobac-
teria (41), nor by a BCG revaccination strategy (22, 43). A TB
subunit vaccine could therefore fulfill the criterion of having
consistently high efficacy in different populations and may have
a particularly important use for revaccination of third world
children in adolescence.
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